Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
Abstract Multiple myeloma (MM) is the second most common hematologic malignancy, and is characterized by the clonal expansion of malignant plasma cells. Despite the recent improvement in patient outcome due to the use of novel therapeutic agents and stem cell transplantation, all patients eventually...
Main Authors: | Yi Fang, Jian Hou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Military Medical Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40779-021-00302-x |
Similar Items
-
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
by: Shrivastava T, et al.
Published: (2023-06-01) -
B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages
by: Shirin Teymouri Nobari, et al.
Published: (2022-02-01) -
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
by: Abhinava K. Mishra, et al.
Published: (2023-11-01) -
Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma
by: Tiantian Ma, et al.
Published: (2021-11-01) -
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
by: Nadeem O, et al.
Published: (2020-10-01)